SHPG - Shire plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
168.95
-0.66 (-0.39%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close169.61
Open169.37
Bid168.05 x 800
Ask172.00 x 1100
Day's Range168.10 - 169.86
52 Week Range123.73 - 190.37
Volume731,606
Avg. Volume1,538,093
Market Cap51.022B
Beta1.45
PE Ratio (TTM)12.03
EPS (TTM)14.04
Earnings DateN/A
Forward Dividend & Yield1.05 (0.62%)
Ex-Dividend Date2018-03-08
1y Target Est201.83
Trade prices are not sourced from all markets
  • Roche Proves Again Why It Will Likely Rout Shire's Hemophilia Business
    Investor's Business Daily7 hours ago

    Roche Proves Again Why It Will Likely Rout Shire's Hemophilia Business

    Roche jumped early Monday on unsurprisingly strong data for its hemophilia treatment, Hemlibra — prodding shares of Shire to slip.

  • GlobeNewswire22 hours ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • Financial Timesyesterday

    [$$] Takeda says Shire deal will boost resilience against price pressures

    will strengthen the Japanese group’s focus on innovative medicines and make it more “resilient” to pricing pressures in the US, its chief executive has said. , Mr Weber said, had been designed “in a way” that meant the combined company “would be very resilient and prepared for an environment which will become tougher”. In 2017, the US accounted for 66 per cent of Shire’s $15bn sales.

  • Benzinga2 days ago

    Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching

    The biotech analysts at Cantor Fitzgerald have a packed calendar: here are some of the dates they’re tracking and why they’re important. Mallinckrodt PLC (NYSE: MNK ) is expected to release Phase 4 interim ...

  • GlobeNewswire4 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • Takeda CEO prescribes surgical R&D cuts after $62 billion Shire deal
    Reuters5 days ago

    Takeda CEO prescribes surgical R&D cuts after $62 billion Shire deal

    For Christophe Weber, the boss of Japan's Takeda Pharmaceutical , securing a $62 billion (46 billion pound) deal last week to buy drugmaker Shire (SHP.L) at the fifth time of asking was the easy bit. At the same time he must win shareholders' support for the largest-ever overseas purchase by a Japanese company - something he told Reuters could be helped by bringing in one or more long-term, large strategic investor.

  • Biogen, Shire called out by FDA for ‘gaming’ generic access rule
    American City Business Journals5 days ago

    Biogen, Shire called out by FDA for ‘gaming’ generic access rule

    The FDA’s decision to publish a list of companies accused of blocking access to their product samples is part of a broader effort by the Trump administration to address high drug costs.

  • Reuters5 days ago

    FOCUS-Takeda CEO prescribes surgical R&D cuts after $62 bln Shire deal

    For Christophe Weber, the boss of Japan's Takeda Pharmaceutical, securing a $62 billion deal last week to buy drugmaker Shire at the fifth time of asking was the easy bit. At the same time he must win shareholders' support for the largest-ever overseas purchase by a Japanese company - something he told Reuters could be helped by bringing in one or more long-term, large strategic investor. When you combine two pipelines you can be more stringent," he said in London, where he is meeting investors and analysts.

  • GlobeNewswire6 days ago

    Shire plc: Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • PR Newswire7 days ago

    Shire Recognizes MPS Awareness Day 2018 with Digital Campaign and Global Events Focused on Increasing Diseases Awareness

    LEXINGTON, Mass., May 15, 2018 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) announces its third annual #FlyforMPS campaign to allow rare champions around the world to recognize and raise awareness for patients and caregivers affected by MPS (mucopolysaccharide) diseases. Shire's #FlyforMPS campaign was created in support of MPS Awareness Day, held annually on May 15th. The campaign was developed in collaboration with the National MPS Society and U.K. MPS Society.

  • GlobeNewswire7 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • Motley Fool7 days ago

    Takeda and Shire: A Pricey Marriage

    A deal gets done, but the costs are high.

  • Motley Fool7 days ago

    Will athenahealth Be the Next Big Healthcare Deal?

    Activist investors want to do a deal, but management might not be willing.

  • Is There An Opportunity With Shire plc’s (LON:SHP) 26% Undervaluation?
    Simply Wall St.8 days ago

    Is There An Opportunity With Shire plc’s (LON:SHP) 26% Undervaluation?

    I am going to run you through how I calculated the intrinsic value of Shire plc (LSE:SHP) using the discounted cash flow (DCF) method. If you want to learn moreRead More...

  • Value Stocks Investors Love
    Simply Wall St.9 days ago

    Value Stocks Investors Love

    Companies, such as Trading Emissions, trading at a market price below their true values are considered to be undervalued. There’s a few ways you can determine how much a companyRead More...

  • Iconic Genzyme building faces uncertain future after Shire-Takeda deal
    American City Business Journals11 days ago

    Iconic Genzyme building faces uncertain future after Shire-Takeda deal

    Shire had been planning to move into the building early next year. Takeda's $62 billion buyout this week could throw a wrench in the works.

  • GlobeNewswire11 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • GlobeNewswire11 days ago

    Caladrius Biosciences Reports 2018 First Quarter Financial Results

    BASKING RIDGE, N.J., May 10, 2018-- Caladrius Biosciences, Inc., a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, ...

  • Recent Developments, Recommendations for JAZZ in May
    Market Realist11 days ago

    Recent Developments, Recommendations for JAZZ in May

    In May, Jazz Pharmaceuticals (JAZZ) submitted a supplemental new drug application (or sNDA) to the FDA for the label expansion of Xyrem for the inclusion of its use in the treatment of cataplexy and EDS (excessive daytime sleepiness) in pediatric patients with narcolepsy. In April, Jazz Pharmaceuticals entered into an agreement with Spark Therapeutics (ONCE) whereby Jazz would purchase a rare pediatric disease priority review voucher for $110 million that would allow it to accelerate the FDA review process for one of its future regulatory submissions. Of the 23 analysts tracking Jazz Pharmaceuticals in May, six have recommended “strong buys” on the stock, while 13 have recommended “buys.” Four analysts have recommended “holds” on Jazz Pharmaceuticals in May.

  • How Did Jazz Pharmaceuticals Perform in 1Q18?
    Market Realist12 days ago

    How Did Jazz Pharmaceuticals Perform in 1Q18?

    In 1Q18, Jazz Pharmaceuticals (JAZZ) generated revenue of $444.6 million compared to $376.1 million in 1Q17, which reflected an ~18% rise on a YoY (year-over-year) basis and a ~2% rise quarter-over-quarter.

  • Whisky and Apologies Aided Takeda's $62 Billion Gamble on Shire
    Bloomberg12 days ago

    Whisky and Apologies Aided Takeda's $62 Billion Gamble on Shire

    Takeda Pharmaceutical Co.’s ambitions for expansion in the lucrative U.S. health-care market led the Japanese drugmaker to begin a painstaking examination of Shire Plc’s assets more than two years prior to striking a $62 billion deal. In particular, Shire’s neuroscience unit and its gastrointestinal products sparked Takeda’s interest. Shire’s struggling stock performance after its failed sale to AbbVie Inc. and the acquisition spree that followed, culminating with the $32 billion takeover of Baxalta Inc., frustrated investors and prompted concerns about its strategy.

  • Takeda Shareholders Should Come Around to Shire
    Bloomberg12 days ago

    Takeda Shareholders Should Come Around to Shire

    Takeda Pharmaceutical Co. investors may belatedly be coming around to the view that the $62 billion purchase of Shire Plc is the best thing that could have happened to the Japanese drugmaker. To get the same U.S. exposure, and generate cost savings, Takeda might have looked to Celgene Corp. or Biogen Inc., according to Datamonitor Healthcare analyst Edward Thomason. Tack on the 65 percent premium Takeda offered Shire shareholders and you’re talking an awful lot of money.

  • Business Wire12 days ago

    SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Shire plc And Encourages Investors To Contact The Firm For Additional Information

    The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Shire plc (SHPG) (“Shire” or the “Company”) relating to the proposed buyout of Shire by Takeda Pharmaceutical Company Limited. Under the terms of the agreement, Shire shareholders are anticipated to receive $30.33 in cash and either 0.839 Takeda shares or 1.678 Takeda American Depositary Shares for each share of Shire common stock held.

  • Moody's12 days ago

    Shire Acq Inv Ireland Designated Activity Co -- Moody's reviews Shire's Baa3 ratings for upgrade

    Moody's Investors Service ("Moody's") placed the ratings of Shire plc ("Shire") and subsidiaries under review for upgrade. This rating action follows the announcement that Shire's board recommends that shareholders vote in favor of Takeda Pharmaceutical Company Limited's offer to acquire Shire for approximately JPY6.7 trillion (USD62 billion). Takeda's rating is A2 under review for possible downgrade, and the rating review of Shire will be tied to the ongoing rating review of Takeda.